• Parmar Unnati Sanjaysinh

In immunocompromised patients, mucormycosis is a life-threatening fungal infection. Despite the fact that these infections are becoming more common, survival rates are still extremely low. Future therapies could benefit from a better understanding of the disease's pathogenesis. Deferoxamine, for example, predisposes patients to mucormycosis by improperly supplying the fungus with iron. These findings suggest that iron chelator therapy could be beneficial in treating the infection, as long as the chelator does not provide the fungus with iron in an inappropriate manner. The use of high-dose liposomal amphotericin as a monotherapy for mucormycosis has been supported by recent research. There are, however, a number of novel therapeutic options. Combination therapy with lipid-based amphotericin, an echinocandin, or an azole (most commonly itraconazole or Posaconazole) or all three of these options are available. Rapid diagnosis, reversal of underlying predisposition, and urgent surgical debridement remain the guiding principles of treatment for this disease.

Mucormycosis, Zygomycosis.

"Mucormycosis - An Overview", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.9, Issue 2, page no.e65-e69, February-2022, Available :http://www.jetir.org/papers/JETIR2202410.pdf

"Mucormycosis - An Overview", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.9, Issue 2, page no. ppe65-e69, February-2022, Available at : http://www.jetir.org/papers/JETIR2202410.pdf